BioAtla (NASDAQ:BCAB) Announces Earnings Results

BioAtla (NASDAQ:BCAB) issued its earnings results on Friday. The company reported ($4.22) EPS for the quarter, beating analysts’ consensus estimates of ($10.00) by $5.78, FiscalAI reports.

BioAtla Stock Performance

Shares of BCAB traded down $0.10 during trading hours on Friday, hitting $4.27. 27,443 shares of the company were exchanged, compared to its average volume of 45,986. The company has a market cap of $7.08 million, a PE ratio of -0.08 and a beta of 0.81. The firm’s 50 day moving average is $6.25 and its 200-day moving average is $19.75. BioAtla has a 52 week low of $3.92 and a 52 week high of $71.50.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded BioAtla to a “hold” rating in a research note on Saturday, April 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BioAtla has an average rating of “Hold” and a consensus target price of $200.00.

Institutional Trading of BioAtla

Large investors have recently made changes to their positions in the stock. Woodline Partners LP bought a new stake in shares of BioAtla during the 1st quarter worth about $26,000. ADAR1 Capital Management LLC bought a new stake in shares of BioAtla during the 4th quarter worth about $104,000. Susquehanna International Group LLP boosted its stake in shares of BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after acquiring an additional 177,760 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of BioAtla by 55.4% during the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in shares of BioAtla during the 3rd quarter worth about $235,000. Institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.